| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153) | M.D. Anderson Cancer Center | 2022-02-14 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760) | Academic and Community Cancer Research United | 2021-06-16 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events (NCT05038254) | M.D. Anderson Cancer Center | 2021-05-12 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313) | National Cancer Institute (NCI) | 2020-11-16 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (NCT04248452) | ECOG-ACRIN Cancer Research Group | 2020-05-26 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer (NCT04220827) | M.D. Anderson Cancer Center | 2019-12-06 |
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499) | City of Hope Medical Center | 2019-04-19 |
| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847) | M.D. Anderson Cancer Center | 2018-02-09 |